✦ LIBER ✦

0177 Primary endocrine therapy versus chemotherapy in postmenopausal patients with ER-positive breast cancer: 5-year results

✍ Scribed by V.F. Semiglazov; G.A. Dashyan; V.V. Semiglazov; E.K. Ziltsova; A.A. Malodusheva; V.G. Ivanov; R.V. Donskih; A.A. Bozhok; R.M. Paltuev; L.M. Berstein

Book ID: 114316306
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 53 KB
Volume: 18
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(09)70200-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Primary endocrine therapy vs chemotherap

Primary endocrine therapy vs chemotherapy in postmenopausal ER-positive breast cancer patients

✍ V. Semiglazov; Kletsel; E. Zhiltsova; V. Ivanov; G. Dashyan; A. Bozhok; O. Melni 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Phase 2 randomized trial of primary endo

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

✍ Vladimir F. Semiglazov; Vladislav V. Semiglazov; Garik A. Dashyan; Elena K. Zilt 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

## Abstract ## BACKGROUND. Few studies have compared primary neoadjuvant endocrine therapy with neoadjuvant chemotherapy in breast cancer patients. The need for preoperative chemotherapy with doxorubicin or taxanes may be reduced in postmenopausal patients with estrogen receptor (ER)‐positive and/

P85 Direct comparison of primary (neoadj

P85 Direct comparison of primary (neoadjuvant) endocrine therapy vs primary chemotherapy in postmenopausal women with ER-positive breast cancer

✍ V. Semiglazov; V. Ivanov; A. Bozhok; A. Kletzel; E. Ziltzova; O. Melnikova; R. P 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Exemestane versus anastrozole as front-l

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer : Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial

✍ Antonio Llombart-Cussac; Amparo Ruiz; Antonio Antón; Agustí Barnadas; Silvia Ant 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

Phase II trial with letrozole (2.5 mg) t

Phase II trial with letrozole (2.5 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer

✍ A. Llombart; Galán; C. Fuster; E. Buch; V. Carañana; A. Rodriguez-Lescure; C. Vá 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 131 KB

2044 POSTER Phase II trial with letrozol

2044 POSTER Phase II trial with letrozole (2.5 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer

✍ A. Llombart Cussac; A. Galán; C. Fuster; E. Buch; V. Carañana; A. Rodríguez Lesc 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 56 KB